Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Disclaimer
Except for the historical information contained herein, statements in this presentation and the subsequent
discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may",
"expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective",
"goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may
constitute "forward-looking statements“. These forward looking statements involve a number of risks, uncertainties
and other factors that could cause actual results to differ materially from those suggested by the forward-looking
statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our
strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological
changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks.
The Company does not undertake any obligation to update forward-looking statements to reflect events or
circumstances after the date thereof.
2
A New Horizon – Pure Play Animal Healthcare
Evolution to a robust SeQuent
4
^The Board of Directors meeting held on February 3, 2017 approved in principle demerger of Human API Biz to a separate entity to be listed in BSE / NSE
Differential market attributes, Alivira’s distinctive approach
Unique Animal
Indian Pharma
Health/Veterinary Alivira’s Approach
Approach
characteristics
5
Differential market attributes, Alivira’s distinctive approach
Unique Animal
Indian Pharma
Health/Veterinary Alivira’s Approach
Approach
characteristics
• Industry driven by patent • Few products under patent Customized R&D approach
expiry protection • Smart program with focus
• High R & D focus with • Limited R&D focussed on on API & Formulations
large filings in US drug delivery & ease of use • Multiple approaches
leveraging local knowledge
• Complex regulatory
framework driving • Smart usage of resources
6
Animal Health- The BEST of both worlds
7
Alivira- India’s largest animal Health Company
Formulations APIs
• Focus on global livestock market with 95+ • Wide range of products, predominantly in
an organic-inorganic led strategy to Countries Anthelmintics & emerging NSAID portfolio
accelerate expansion • Established relationship with top 10
25% veterinary companies with a steady
• Strong presence in Europe, LATAM,
Turkey, India, Africa & South East Asia customer base across US, Europe, LATAM
25% APIs
450+ 4 12 23 2 30+
Finished Manufacturing Dosage Commercial Manufacturing Filings
Dosages Facilities Formats APIs Facilities
75% Formulations
8
Advantageously placed in a growing opportunity
11.7
Industry to grow at a CAGR of ~7%
16.8
25.1
2014 18.1 with Production animal segment 2019
having the larger pie
Focus Area
Production Animals
Companion Animals
Global population
growth & focus
Increased Productivity on well being Increased
demand improvements of animals Increased
pet ownership
for animal medicalization
Changing global
protein for pets
lifestyle &
evolving habits
Heightened
Unmet
focus
medical
on food safety
needs
9
*Figures in US$ billion.
Animal health – Large Growing and Diverse Sector
Total Animal Health Market Size (US$bn) CAGR
6.8
2010-14 2014-19
10.7
4.6 6.6% 7.2%
3.4 7.2
11.9 7.8% 8.1%
5.3
8.6
6.8 8.0% 8.2%
9.3 12.6
7.5 6.0% 6.7%
15.8 20.0
8.9 11.4 13.9
10.5 6.1
3.6 4.5
2010 2014 2019 2010 2014 2019 2010 2014 2019
Presence
Alivira’s
10
Fast expanding market coverage
14%
20%
52%
15%
Europe
LATAM
Emerging Markets
Turkey 95+ countries and progressing
11
Strong Management team
Ramon Vila Jose Nunes Filho Dr. Huseyn Aydin Dr. Sumit Saxena
Business Europe Business LATAM Business Turkey Business Emerging Markets
12
Formulations – Skill & Scale
A steady foundation for global expansion
Differentiators
11
Across Multiple Geographies
15
Across Multiple Geographies
APIs APIs
Oral Solution
Oral Solution
Liquid for inhalation
Liquid for inhalation
Oral Suspension
Oral Suspension
Water Soluble Powder
Water Soluble Powder
Drug Premix
Drug Premix
Nutritional Feed Add.
Nutritional Feed Add.
Tablets
Pre Filled Syringes Pre Filled Syringe
Tablet Injectable
Gases
Gases
Aerosols
Aerosols
Pour On / Spot On
Pour-on/ Spot-on
Disinfectants
Disinfectants
In Process In Process 17
API Edge In Animal Health
Comprehensive API Business
Our dedicated USFDA approved facility at Vizag – 1st in the world
Anthelmentic
Business
43%
• Offers a 23 products globally
• Long standing relationships with global Top 10 animal
Antiemetic health companies
3%
Ecto-Parasiticides 3%
Beta Agonist 3%
3% 20% Key Products
Antibiotic Antiprotozoal
5% • Triclabendazole, Flunixin, Clorsulon, Fenbendazole,
Supplements 20% Albendazole & Praziquantel
Strategic Progression
70%
Commercialized
• Expanding portfolio into newer therapeutic segments
12%
• Leveraging key existing customer relationships to expand
Under Feasibility
18% product basket across geographies
Under Development
19
USFDA Approved Veterinary API facility
Company B 6 4 5
Company C 4 0 4
Company D 1 1 1
Company E 4 1 4
Company F 5 3 3
Company G 1 3 5
Company H 1 1 1
Company I 4 4 3
Company J 6 2 6
21
Future Strategy
Future Strategy
23
Human APIs
Human APIs
• Proposed Company to be
amongst the largest
standalone API
companies
Pre-2013 2016-17
Demerged the commodity API business of Demerged Human API business from SeQuent
Strides Shasun while retaining the captive APIs to operate as Pure Play animal healthcare
for the formulations operations company
Expansion across the regulated markets with Organic growth with over 80% regulated
key approvals and compliance record market business along with profit sharing
partnerships
Investments across the facilities to make it Strategic recourse to focus on market APIs
future ready on quality and EHS offering supply chain security for regulated
markets
Strides Arcolab merged with Shasun Pharma to Started journey as an unregulated API
integrate its formulations and secure API manufacturer
capabilities
26
Solara Active Pharma Sciences
29
Business Performance
Net Sales (INR mn) Net Loss (INR mn)
11
9,151
6,214
4,654
-180
-667
FY15 FY16 FY17
21
-14
-264
881
305
552
4,302
5,979
3,672
2,870
5,642
5,374
5.2
1.8
1.7
1.3
0.3
0.4
FY15 FY16 FY17 FY15 FY16 FY17
Investment to acquire growth assets, key ratios improved
31
* FY16-17 & FY15-16 figures as per Ind AS; FY14-15 as per Indian GAAP
Takeaway- Aiming to become a Top 10 Animal Health Company by FY22